ACUTA CAPITAL PARTNERS, LLC - Q1 2018 holdings

Add to watchlist

$612 Million is the total value of ACUTA CAPITAL PARTNERS, LLC's 59 reported holdings in Q1 2018. The portfolio turnover from Q4 2017 to Q1 2018 was 79.6% .

All

			Value		Shares		↓ Weighting
IMMU	Sell	IMMUNOMEDICS INC	$85,469,000	-21.6%	5,850,000	-13.3%	13.96%	-32.2%
IWM	Sell	ISHARES TRput	$30,367,000	-20.3%	200,000	-20.0%	4.96%	-31.1%
VRAY	Sell	VIEWRAY INC	$11,914,000	-32.8%	1,852,878	-3.3%	1.95%	-41.9%
FXI	Sell	ISHARES TRput	$3,543,000	-23.3%	75,000	-25.0%	0.58%	-33.6%
MRTX	Sell	MIRATI THERAPEUTICS INC	$3,070,000	+8.5%	100,000	-35.5%	0.50%	-6.2%
	Sell	NABRIVA THERAPEUTICS PLC	$2,815,000	-18.8%	559,739	-3.5%	0.46%	-29.8%
RMTI	Sell	ROCKWELL MED INCput	$1,589,000	-38.0%	305,000	-30.7%	0.26%	-46.3%
AMAG	Sell	AMAG PHARMACEUTICALS INCput	$1,008,000	-42.6%	50,000	-62.3%	0.16%	-50.3%
OSUR	Sell	ORASURE TECHNOLOGIES INCput	$845,000	-55.2%	50,000	-50.0%	0.14%	-61.2%
GKOS	Sell	GLAUKOS CORPput	$617,000	-22.4%	20,000	-35.5%	0.10%	-32.7%
MNKD	Sell	MANNKIND CORPput	$302,000	-24.5%	132,500	-23.2%	0.05%	-35.5%
AVEO	Exit	AVEO PHARMACEUTICALS INCcall	$0	–	-12,000	-100.0%	-0.01%	–
MNTA	Exit	MOMENTA PHARMACEUTICALS INCput	$0	–	-2,500	-100.0%	-0.01%	–
TGTX	Exit	TG THERAPEUTICS INCcall	$0	–	-10,000	-100.0%	-0.02%	–
NEOS	Exit	NEOS THERAPEUTICS INCput	$0	–	-25,000	-100.0%	-0.05%	–
LXRX	Exit	LEXICON PHARMACEUTICALS INCput	$0	–	-32,500	-100.0%	-0.06%	–
AVEO	Exit	AVEO PHARMACEUTICALS INC	$0	–	-124,338	-100.0%	-0.07%	–
EVH	Exit	EVOLENT HEALTH INCcall	$0	–	-32,500	-100.0%	-0.08%	–
ONCE	Exit	SPARK THERAPEUTICS INCput	$0	–	-10,000	-100.0%	-0.10%	–
MDXG	Exit	MIMEDX GROUP INCput	$0	–	-50,000	-100.0%	-0.12%	–
FOLD	Exit	AMICUS THERAPEUTICS INC	$0	–	-43,900	-100.0%	-0.12%	–
MNTA	Exit	MOMENTA PHARMACEUTICALS INCcall	$0	–	-46,300	-100.0%	-0.12%	–
EVTC	Exit	EVERTEC INCput	$0	–	-55,000	-100.0%	-0.14%	–
ATRA	Exit	ATARA BIOTHERAPEUTICS INCput	$0	–	-55,000	-100.0%	-0.19%	–
IMDZ	Exit	IMMUNE DESIGN CORP	$0	–	-274,100	-100.0%	-0.20%	–
MDCO	Exit	MEDICINES COcall	$0	–	-40,000	-100.0%	-0.21%	–
VRAY	Exit	VIEWRAY INCcall	$0	–	-120,000	-100.0%	-0.21%	–
FPRX	Exit	FIVE PRIME THERAPEUTICS INCput	$0	–	-52,500	-100.0%	-0.22%	–
NEOS	Exit	NEOS THERAPEUTICS INCcall	$0	–	-115,500	-100.0%	-0.22%	–
NVTA	Exit	INVITAE CORP	$0	–	-152,300	-100.0%	-0.26%	–
TDOC	Exit	TELADOC INCput	$0	–	-40,000	-100.0%	-0.26%	–
EXEL	Exit	EXELIXIS INCcall	$0	–	-50,000	-100.0%	-0.29%	–
SGEN	Exit	SEATTLE GENETICS INCput	$0	–	-30,000	-100.0%	-0.30%	–
STML	Exit	STEMLINE THERAPEUTICS INCcall	$0	–	-105,000	-100.0%	-0.31%	–
NTLA	Exit	INTELLIA THERAPEUTICS INCcall	$0	–	-86,000	-100.0%	-0.31%	–
JUNO	Exit	JUNO THERAPEUTICS INCcall	$0	–	-37,000	-100.0%	-0.32%	–
NKTR	Exit	NEKTAR THERAPEUTICSput	$0	–	-30,000	-100.0%	-0.34%	–
CRSP	Exit	CRISPR THERAPEUTICS AGcall	$0	–	-80,000	-100.0%	-0.36%	–
EDIT	Exit	EDITAS MEDICINE INCcall	$0	–	-64,000	-100.0%	-0.37%	–
VRX	Exit	VALEANT PHARMACEUTICALS INTLcall	$0	–	-100,000	-100.0%	-0.39%	–
RARE	Exit	ULTRAGENYX PHARMACEUTICAL INcall	$0	–	-46,000	-100.0%	-0.40%	–
NKTR	Exit	NEKTAR THERAPEUTICScall	$0	–	-36,000	-100.0%	-0.41%	–
ACRS	Exit	ACLARIS THERAPEUTICS INC	$0	–	-92,500	-100.0%	-0.43%	–
AGIO	Exit	AGIOS PHARMACEUTICALS INCput	$0	–	-40,000	-100.0%	-0.43%	–
ACAD	Exit	ACADIA PHARMACEUTICALS INCcall	$0	–	-80,000	-100.0%	-0.46%	–
LOXO	Exit	LOXO ONCOLOGY INCput	$0	–	-30,000	-100.0%	-0.48%	–
ACAD	Exit	ACADIA PHARMACEUTICALS INC	$0	–	-90,000	-100.0%	-0.51%	–
GBT	Exit	GLOBAL BLOOD THERAPEUTICS INcall	$0	–	-80,000	-100.0%	-0.59%	–
SGEN	Exit	SEATTLE GENETICS INCcall	$0	–	-80,000	-100.0%	-0.81%	–
MNTA	Exit	MOMENTA PHARMACEUTICALS INC	$0	–	-311,169	-100.0%	-0.82%	–
BCRX	Exit	BIOCRYST PHARMACEUTICALS	$0	–	-900,000	-100.0%	-0.83%	–
EVH	Exit	EVOLENT HEALTH INCcl a	$0	–	-420,000	-100.0%	-0.98%	–
EDGE	Exit	EDGE THERAPEUTICS INC	$0	–	-943,906	-100.0%	-1.67%	–
ZGNX	Exit	ZOGENIX INC	$0	–	-300,000	-100.0%	-2.27%	–

Original filings

The following EDGAR filing(s) were analyzed to create this report:

View 13F-HR filed 2018-05-15

Signatures

The EDGAR filing(s) were signed by:

Manfred Yu — Chief Compliance Officer & Chief Operating Officer

Top long-term holdings

Name	Quarters owned	Latest quarter owned	Max weighting
IOVANCE BIOTHERAPEUTICS INC	24	Q1 2023	21.2%
IRIDEX CORP	20	Q3 2019	8.1%
ARROWHEAD PHARMACEUTICALS INC	20	Q2 2023	7.9%
IMMUNOMEDICS INC	19	Q3 2020	20.6%
VERACYTE INC	19	Q3 2019	10.1%
ASCENDIS PHARMA A S	18	Q2 2020	7.2%
XENON PHARMACEUTICALS INC	18	Q3 2022	4.6%
CAS MED SYS PAR $0.004	18	Q1 2019	6.4%
APELLIS PHARMACEUTICALS INC	17	Q3 2023	18.4%
KURA ONCOLOGY INC. COMMON STOCK	17	Q3 2023	8.1%

View ACUTA CAPITAL PARTNERS, LLC's complete holdings history.

Latest significant ownerships (13-D/G)

ACUTA CAPITAL PARTNERS, LLC Q1 2018 significant holdings filed using form 13D/G when ownership exceeds 5% of a company's total stock issue.
	Filed	Shares	Percentage
BCLS Acquisition Corp.^{Sold out}	February 14, 2023	0	0.0%
Jiya Acquisition Corp.^{Sold out}	February 14, 2023	0	0.0%
VistaGen Therapeutics, Inc.^{Sold out}	February 14, 2023	0	0.0%
Larimar Therapeutics, Inc.^{Sold out}	February 15, 2022	0	0.0%
CATALYST BIOSCIENCES, INC.^{Sold out}	February 14, 2022	0	0.0%
Aadi Bioscience, Inc.	September 07, 2021	1,529,402	7.2%
Kadmon Holdings, Inc.	February 14, 2020	7,373,333	4.6%
IRIDEX CORP^{Sold out}	November 13, 2019	0	0.0%
ASSEMBLY BIOSCIENCES, INC.	February 14, 2019	718,500	2.8%
CAS MEDICAL SYSTEMS INC	February 14, 2019	5,263,508	18.2%

View ACUTA CAPITAL PARTNERS, LLC's complete significant-ownership history.

Latest filings

Type	Filed
13F-HR	2024-05-15
13F-HR	2024-02-14
13F-HR	2023-11-14
13F-HR	2023-08-14
13F-HR	2023-05-15
SC 13G/A	2023-02-14
SC 13G/A	2023-02-14
SC 13G/A	2023-02-14
13F-HR	2023-02-14
13F-HR	2022-11-14

View ACUTA CAPITAL PARTNERS, LLC's complete filings history.

All filings

View complete filings history.

Compare quarters

Export ACUTA CAPITAL PARTNERS, LLC's holdings